InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,730.86
(
0.21%
)
US TECH 100
19,370.40
(
0.25%
)
Dow Jones
42,171.19
(
0.11%
)
Brent Oil
74.48
(
1.00%
)
Bitcoin
63,211.80
(
-0.18%
)
Post# of 27676
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

GoHighOrGoHigh

Send PM Follow Ignore
Followers 27
Posts 3328
Boards Moderated 0
Alias Born 08/17/2009

GoHighOrGoHigh

Re: None

Wednesday, 10/07/2015 9:52:14 AM

Wednesday, October 07, 2015 9:52:14 AM

Post# of 27676
BEVERLY HILLS, Calif., Oct. 7, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company") announced today it has entered into an agreement with Theradex Systems, Inc. ("Theradex"), a leading global contract research organization ("CRO") with extensive expertise in oncology clinical development. Through this new partnership, Theradex will lead the Company in finalizing the Investigational New Drug Application (IND #124642) with the U.S. FDA for Rich's lead drug RP-323 in patients with AML.

No one gives a _ about the price you paid for your shares or the price at which you were able to sell them.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up